APPLE WINS IMPORT BAN CASE FOR REDESIGNED WATCHES

The ITC terminated the case and upheld a preliminary ruling from March, determining that Apple's redesigned smartwatches do not infringe on relevant patents. This marks a significant legal victory for Apple, which faced potential restrictions on selling one of its key product lines. The company had previously redesigned its blood-oxygen monitoring feature to address patent infringement concerns raised by medical technology competitor Masimo. The redesign successfully cleared the regulatory hurdle, eliminating the threat of an import ban that could have disrupted Apple Watch sales. The decision allows Apple to maintain its current manufacturing and distribution strategy without interruption. The case centered on whether Apple's technology violated patents related to blood-oxygen detection in wearable devices. With the ITC's ruling, Apple can continue selling its smartwatches in the US market without the restrictions an import ban would have imposed.